Overview

A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis

Status:
Completed

Trial end date:
2019-01-29

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effects of of rosuvastatin 20 mg compared to placebo for treating Chinese patients with subclinical atherosclerosis.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Rosuvastatin Calcium